ArticleBMC cancer2020
Establishment and validation of a nomogram with intratumoral heterogeneity derived from
Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Prediction of local recurrence in cohorts of head and neck cancer patients after intensity-modulated radiation therapy based on CT radiomics: A double-center observation study.Translational oncology · 2026Article
- Automated segmentation of the primary tumor in nasopharyngeal carcinoma using a deep learning framework in positron emission tomography imaging: a comparative study.Quantitative imaging in medicine and surgery · 2025Article
- Role of PET/CT in improving the cost effectiveness of nimotuzumab in nasopharyngeal carcinoma.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2024Article
- Novel prediction model combining PET/CT metabolic parameters, inflammation markers, and TNM stage: prospects for personalizing prognosis in nasopharyngeal carcinoma.Annals of nuclear medicine · 2024Article
- Prognostic value of lymph node-to-primary tumor ratio of PET standardized uptake value for nasopharyngeal carcinoma: a recursive partitioning risk stratification analysis.Therapeutic advances in medical oncology · 2024Article
- PretreatmentCancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Four-dimensional quantitative analysis using FDG-PET in clinical oncology.Japanese journal of radiology · 2023Review
- Development and validation of a [European radiology · 2023Article
- Nomogram for distant metastasis-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Article
- A diagnosis model in nasopharyngeal carcinoma based on PET/MRI radiomics and semiquantitative parameters.BMC medical imaging · 2022Article
- Prognostic significance of MRI-based late-course tumor volume in locoregionally advanced nasopharyngeal carcinoma.Radiation oncology (London, England) · 2022Article
- Prediction of 5-year progression-free survival in advanced nasopharyngeal carcinoma with pretreatment PET/CT using multi-modality deep learning-based radiomics.Frontiers in oncology · 2022Article
- PretreatmentAnnals of nuclear medicine · 2021Article
- Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area.Cancer research and treatment · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIntratumoral heterogeneity has an enormous effect on patient treatment and outcome. The purpose of the current study was to establish and validate a nomogram with intratumoral heterogeneity derived from
methodsA total of 171 NPC patients who underwent pretreatment
resultsFor the primary tumor, MTV-2.5, TLG-2.5, MTV-70%, and TLG-70% were significantly correlated with PFS. For the maximal neck lymph node, short diameter and HI were significantly correlated with PFS. Among the clinicopathologic parameters, M stage was a significant prognostic factor for recurrence. In multivariate analysis, M stage (P = 0.006), TLG-T-70% (P = 0.002), and HI-N (P = 0.018) were independent predictors. Based on this prognostic model, a nomogram was generated. The C-index of this model was 0.74 (95% CI: 0.63-0.85). For the cross validation, the C-index for the model was 0.73 (95% CI: 0.62-0.83) with the validation cohort. Patients with a risk score of ≥111 had poorer survival outcomes than those with a risk score of 0-76 and 77-110.
conclusionsIntratumoral heterogeneity derived from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.